Planning/in-life/histology/reporting will be several months. On the plus side we know IMP761 crosses to cyno from the efficacy modeling that feels forever ago. For ethical and cost considerations my hope is rodent proves sufficient as a species model. If all goes well first in human next year. I wouldn’t expect full tox package data until first half next year.
Ann: Immutep granted US patent for IMP761 agonist LAG-3 antibody, page-20
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.0¢ | $833.4K | 2.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 388130 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 39940 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |